get a key
steadybase-$ company SVRA
account_id none on file
legal_name Savara Inc
ticker SVRA
cik 1160308
domain savarapharma.com
entry_point_account_id none on file
name Savara Inc.
exchange Nasdaq
sector Health Care
hq Austin, TX, United States
calls 0 filings 3 executives 3 family 0
why_nownone on file
callsnone on file
filings
The increase was primarily attributable to $7.5 million of higher personnel costs, driven by increased stock-based compensation expense as well as increased headcount growth as we build out our commercial team ahead of and in support of our planned product launch, in addition to an increase of $0.8 million in certain commercial activities.

filing / Aug 11, 2026 / receipt

The increase was primarily attributable to $13.6 million of higher personnel costs, driven by increased stock-based compensation expense as well as increased headcount growth as we build out our commercial team ahead of and in support of our planned product launch; an increase of $0.5 million in certain commercial activities and an increase of $0.6 million in departmental overhead.

filing / Aug 11, 2026 / receipt

Since the Company gained control of the underlying assets on the date that early access was granted by the landlord, the accounting commencement date for the Company's new office headquarters is May 1, 2026 ("Commencement Date") and continues through November 30, 2031 , with annual rental payments of approximately $ 0.3 million starting July 1, 2026, net of a Tenant Allowance, to be paid in a lump sum, subject to inc

filing / Aug 11, 2026 / receipt

executives
Dave Lowrance CFO linkedin receipt
Matthew Pauls Chief Executive Officer - receipt
Robert Neville Chairman - receipt
familynone on file
upcoming
2026-11-11 earnings call scheduled ir
changes
2022-12-15 Chief Financial and Administrative Officer, appointed sec_8k
2020-12-10 Chief Executive Officer, appointed sec_8k
2020-09-11 Chairman, appointed sec_8k
2017-04-27 Chairman, appointed sec_8k
mcp_package_hint
steadybase-$